youtube_live
Q3 2026 earnings • 12:00 AM tomorrow
See detailschevron_right
AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$27.66
arrow_downward
-1.28%(-0.36) 1D
$27.66
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 5, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMPH...
Open
$28.30
High
$29.21
Low
$27.43
Mkt. cap
1.18B
Avg. vol.
453.05K
Volume
420.30K
P/E ratio
16.18
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.93
Shares outstanding
42.54M
No. of employees
2K
Open
$28.30
High
$29.21
Low
$27.43
Mkt. cap
1.18B
Avg. vol.
453.05K
Volume
420.30K
P/E ratio
16.18
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.93
Shares outstanding
42.54M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Canada
·
23 hours ago
Form 144 Amphastar Pharmaceuticals For: 4 November By Investing.com
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteamphastar.com
Analyst ratings
Based on 6 analysts giving stock ratings to AMPH in the past 3 months
Hold
Buy
0
Hold
5
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AMPH in the last 3 months.
Highest
Current $27.66
$30.00 (+8.46%)
Average
$22.17 (-19.85%)
Lowest
$20.00 (-27.69%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan | Hold | Maintained | $30.00 | +8.5% | 10/22/2026 |
Benjamin Burnett Wells Fargo | Hold | Maintained | $20.00 | -27.7% | 09/02/2026 |
Glen Santangelo Barclays | Hold | Maintained | $23.00 | -16.8% | 08/18/2026 |
Serge Belanger Needham | Hold | Maintained | $20.00 | -27.7% | 08/07/2026 |
David Amsellem Piper Sandler | Hold | Reiterated | $20.00 | -27.7% | 08/07/2026 |
Jason Gerberry Bank of America Securities | Sell | Reiterated | $20.00 | -27.7% | 08/07/2026 |
Chi Meng Fong Bank of America Securities | Hold | Reiterated | $25.00 | -9.6% | 05/07/2026 |
Dennis Ding Jefferies | Hold | Downgraded | $22.00 | -20.5% | 04/21/2026 |
Cerena Chen Wells Fargo | Buy | Maintained | $30.00 | +8.5% | 02/27/2026 |
Pavan Patel Bank of America Securities | Hold | Reiterated | $28.00 | +1.2% | 02/26/2026 |
Next call in 52:01
Tomorrow, 12:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.86
Revenue / Est. (USD)
- / 197.50M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 191.84M | 183.10M | 171.17M | 183.90M |
Cost of goods sold | 93.19M | 97.44M | 100.85M | 90.43M |
Cost of revenue | 93.19M | 97.44M | 100.85M | 90.43M |
Research and development expenses | 22.35M | 23.31M | 26.74M | 22.16M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 27.87M | 26.75M | 29.96M | 31.58M |
Operating expense | 50.23M | 50.06M | 56.69M | 53.74M |
Total operating expenses | 143.42M | 147.50M | 157.54M | 144.17M |
Operating income | 48.42M | 35.61M | 13.63M | 39.73M |
Other non operating income | 231.00K | 215.00K | -1.42M | 1.29M |
EBT including unusual items | 21.51M | 31.91M | 10.05M | 38.54M |
EBT excluding unusual items | 44.61M | 31.91M | 10.05M | 38.54M |
Income tax expense | 4.16M | 7.48M | 3.63M | 8.20M |
Effective tax rate | 19.35% | 23.45% | 36.13% | 21.26% |
Other operating expenses | - | - | - | - |
Net income | 17.35M | 24.43M | 6.42M | 30.35M |
Net profit margin | 9.04% | 13.34% | 3.75% | 16.50% |
Earnings per share | 0.93 | 0.73 | 0.42 | 0.91 |
Interest and investment income | 2.25M | 2.42M | 2.40M | 2.29M |
Interest expense | -6.28M | -6.33M | -4.55M | -4.56M |
Net interest expenses | -4.04M | -3.91M | -2.15M | -2.27M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 62.55M | 49.95M | 27.98M | 54.04M |
Gain or loss from assets sale | 1.00K | 6.00K | 4.00K | 9.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events